江苏南方卫材医药股份有限公司 关于控股股东部分股份解除质押及再质押的公告

Core Viewpoint - The announcement details the shareholding and pledge status of Jiangsu Southern Pharmaceutical Co., Ltd., highlighting the significant share pledges by the controlling shareholder, Li Ping, and the implications for the company's operations and governance [2][4]. Shareholding Summary - As of the announcement date, Li Ping, the controlling shareholder, holds 118,841,048 shares, representing 41.12% of the total share capital. Together with his associates, they hold a total of 136,560,415 shares, accounting for 47.25% of the total share capital [2]. - After the recent share pledge activities, Li Ping has pledged a total of 92,400,000 shares, which is 77.75% of his holdings and 31.97% of the total share capital [2]. Pledge Details - The announcement specifies that the pledged shares do not involve guarantees for major asset restructuring or performance compensation [2]. - The controlling shareholder and associates have a total of 6,440,000 shares maturing in the next six months, which is 22.28% of the total share capital and 47.16% of their holdings. The outstanding pledge financing balance is 12,100 million [3]. - There are no shares maturing in the next year, indicating a manageable pledge risk [3]. Impact on Company Operations - The current share pledges are not expected to significantly impact the company's main business, financing costs, or ongoing operational capabilities [4]. - The pledges will not affect the ability of shareholders to appoint directors or the overall governance structure of the company, ensuring stability in control and management [5]. - There are no performance compensation obligations that the controlling shareholder must fulfill, further indicating a stable outlook for the company [5].